Cargando…

Inhibition of LOXL2 Enhances the Radiosensitivity of Castration-Resistant Prostate Cancer Cells Associated with the Reversal of the EMT Process

INTRODUCTION: Radiotherapy is the mainstay in the treatment of prostate cancer. However, significant radioresistance of castration-resistant prostate cancer (CRPC) cells constitutes a main obstacle in the treatment of this disease. By using bioinformatic data mining methods, LOXL2 was found to be up...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Peng, Yu, Hongliang, Wang, Feijiang, Yan, Feng, He, Xia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369494/ https://www.ncbi.nlm.nih.gov/pubmed/30809541 http://dx.doi.org/10.1155/2019/4012590

Ejemplares similares

LOXL2 Upregulation in Gliomas Drives Tumorigenicity by Activating Autophagy to Promote TMZ Resistance and Trigger EMT
por: Zhang, Qing, et al.
Publicado: (2020)

Autophagy inhibition enhances radiosensitivity of Eca-109 cells via the mitochondrial apoptosis pathway
por: Tao, Hua, et al.
Publicado: (2018)

Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer
por: Chen, Xiaoliang, et al.
Publicado: (2020)

Afatinib Reverses EMT via Inhibiting CD44-Stat3 Axis to Promote Radiosensitivity in Nasopharyngeal Carcinoma
por: Huang, Huichao, et al.
Publicado: (2022)

PLCε knockdown enhances the radiosensitivity of castration-resistant prostate cancer via the AR/PARP1/DNA-PKcs axis
por: Pu, Jun, et al.
Publicado: (2020)

PLCε knockdown enhances the radiosensitivity of castration-resistant prostate cancer via the AR/PARP1/DNA-PKcs axis
por: Pu, Jun, et al.
Publicado: (2022)

Nitroxoline inhibits bladder cancer progression by reversing EMT process and enhancing anti-tumor immunity
por: Xu, Naijin, et al.
Publicado: (2020)

Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity
por: Cherif, Chaïma, et al.
Publicado: (2021)

Potential association of LOXL1 with peritoneal dissemination in gastric cancer possibly via promotion of EMT
por: Hu, Qingjiang, et al.
Publicado: (2020)

ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT)
por: Choi, Jae Duck, et al.
Publicado: (2021)

SGK1 inhibition-induced autophagy impairs prostate cancer metastasis by reversing EMT
por: Liu, Weiwei, et al.
Publicado: (2018)

Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer
por: Sarwar, Sadia, et al.
Publicado: (2022)

The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC
por: Lee, Yun Sun, et al.
Publicado: (2023)

Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair
por: Elsesy, Mohamed E., et al.
Publicado: (2020)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

A Theoretical Approach to Coupling the Epithelial-Mesenchymal Transition (EMT) to Extracellular Matrix (ECM) Stiffness via LOXL2
por: Deng, Youyuan, et al.
Publicado: (2021)

Cleavage of LOXL1 by BMP1 and ADAMTS14 Proteases Suggests a Role for Proteolytic Processing in the Regulation of LOXL1 Function
por: Rosell-García, Tamara, et al.
Publicado: (2022)

Loxl2 and Loxl3 Paralogues Play Redundant Roles during Mouse Development
por: Santamaría, Patricia G., et al.
Publicado: (2022)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer
por: Gu, Peng, et al.
Publicado: (2019)

The interaction of botanicals and AMPK signaling in the inhibition of castrate-resistant prostate cancer
por: Whelan, Jay, et al.
Publicado: (2014)

Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer
por: Kaushik, Akash K., et al.
Publicado: (2016)

20(S)-Protopanaxadiol Inhibition of Progression and Growth of Castration-Resistant Prostate Cancer
por: Cao, Bo, et al.
Publicado: (2014)

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer
por: Pollock, Julie A., et al.
Publicado: (2016)

Testosterone metabolites inhibit proliferation of castration- and therapy-resistant prostate cancer
por: Bremmer, Felix, et al.
Publicado: (2018)

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer
por: Liu, Chengfei, et al.
Publicado: (2016)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Inhibition of ZIP4 reverses epithelial-to-mesenchymal transition and enhances the radiosensitivity in human nasopharyngeal carcinoma cells
por: Zeng, Qi, et al.
Publicado: (2019)

LOXL4, but not LOXL2, is the critical determinant of pathological collagen cross-linking and fibrosis in the lung
por: Ma, Hsiao-Yen, et al.
Publicado: (2023)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

LOXL2 silencing suppresses angiotensin II-induced cardiac hypertrophy through the EMT process and TGF-β1/Smad3/NF-κB pathway
por: Luo, Jun, et al.
Publicado: (2022)

Cisplatin loaded multiwalled carbon nanotubes reverse drug resistance in NSCLC by inhibiting EMT
por: Qi, Yuxin, et al.
Publicado: (2021)

Loss of epithelial AR increase castration resistant stem-like prostate cancer cells and promotes cancer metastasis via TGF-β1/EMT pathway
por: Cai, Qiliang, et al.
Publicado: (2020)

LOXL2 Expression Status Is Correlated With Molecular Characterizations of Cervical Carcinoma and Associated With Poor Cancer Survival via Epithelial-Mesenchymal Transition (EMT) Phenotype
por: Cao, Canhui, et al.
Publicado: (2020)

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
por: Ku, ShengYu, et al.
Publicado: (2014)

Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab
por: Wolff, Johannes M., et al.
Publicado: (2012)

Digitoxin Inhibits Epithelial-to-Mesenchymal-Transition in Hereditary Castration Resistant Prostate Cancer
por: Pollard, Bette S., et al.
Publicado: (2019)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer
por: Gordon, Nicolas, et al.
Publicado: (2023)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h7c603qavdc45v2kepflnhd1hm